(Alliance News) - AstraZeneca PLC on Monday said a breast cancer drug failed to significantly extend patients' lives, a second blow this month to hopes for the product. Datopotamab deruxtecan, also ...

Board members from the European Central Bank are set to speak through the week, with Frank Elderson and Piero Cipollone ...

European shares started the week on a subdued note as investors await significant economic data from the region. The ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab ...

BNP Paribas has agreed to buy the private banking activities of HSBC in Germany, saying the deal would grow is exposure to entrepreneurs in the country. The eurozone’s biggest bank did not disclose ...

AstraZeneca's breast cancer drug datopotamab deruxtecan didn't show a statistical significance in overall survival compared with chemotherapy, results showed at a phase three trial.

London stocks were set to rise at the open on Monday following heavy losses at the end of last week. The FTSE 100 was called ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

London open The FTSE 100 is expected to open 35 points higher on Monday, having closed down 1.19% on Friday at 8,229.99.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

The antibody drug conjugate was discovered by Japanese pharmaceutical company Daiichi Sankyo and is being jointly developed by AstraZeneca and Daiichi Sankyo. The two companies are currently ...